Overview
- Mineralys amended its deal with Tanabe to buy full worldwide rights to lorundrostat for a $200 million upfront payment and up to $365 million in additional commercial payments.
- To fund the upfront cost the company priced an underwritten offering of 5.66 million shares at $26.50, expected to raise about $150 million in gross proceeds.
- Mineralys also secured a staged loan facility of up to $500 million from funds managed by Pharmakon Advisors with access to later tranches tied to FDA approval and sales milestones.
- At ENDO 2026 the company presented a post hoc biomarker analysis showing lorundrostat altered RAAS markers and was linked to declines in NT‑proBNP and other heart‑failure–related biomarkers, a result the company and analysts called hypothesis‑generating and in need of prospective confirmation.
- The combined financing and rights purchase shift value toward commercialization upside but increase near‑term leverage and execution risk, so the company must access future loan tranches and run confirmatory trials to convert early signals into revenue and to meet contingent payments.